The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

Chiefs Hall of Honor member Art Still is a proud foot soldier in the Amyloidosis Army, a nonprofit he started hoping to ...

Immix Biopharma (IMMX) announced that the U.S. FDA has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of ...

Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the ...

The European Commission has granted marketing authorization in the European Union (EU) for acoramidis, under the brand name ...

Bloom is an international name. Olympic skills, engaging personality and sharp business acumen have taken him all over the world ...

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most ...

Insights into the structures could lead to improved treatment strategies for transthyretin amyloidosis, a progressive, fatal disease in men.

February is often celebrated as the month of love, but it's also recognized as American Heart Month, to raise awareness about cardiovascular health.

While healthy transthyretin moves hormones through blood and spinal fluid, misfolded versions of the protein form dangerous clumps in the heart and along nerves-triggering a progressive and fatal ...